刘菁解读:MDS 统一帕金森病评定量表(MDS-UPDRS)

2022-08-06 刘菁 ANDs

刘菁解读:MDS 统一帕金森病评定量表(MDS-UPDRS)

MDS 统一帕金森病评定量表(MDS Unified-Parkinson Disease Rating Scale, MDS-UPDRS):可对疾病严重程度进行全面和详细的评定,包括四大部分:第一部分是评价帕金森病非运动症状对患者日常生活的影响;第二部分是评价帕金森病运动症状对患者日常生活的影响;第三部分是评价帕金森病的运动功能;第四部分评价了运动并发症,异动症和运动波动,包括关期肌张力障碍。

统一帕金森病评定量表(UPDRS 3.0版)

MDS-UPDRS使评分操作更容易,查体更规范。对于发现早期病情更敏感,对于评估非运动症状更可靠,判断病情更合理。目前已将MDS-UPDRS评分法作为帕金森病的一种常规评分方法,是我们进行疾病全程管理的不可或缺的重要工具。

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1842832, encodeId=dc4c1842832cc, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11422, encryptionId=9f061142249, topicName=MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Thu Oct 27 14:40:48 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115234, encodeId=d03c211523487, content=MDS 统一<a href='/topic/show?id=4c671052893a' target=_blank style='color:#2F92EE;'>#帕金森病评定量表#</a>(MDS-UPDRS)<a href='/topic/show?id=bfe3961369b' target=_blank style='color:#2F92EE;'>#量表#</a><a href='/topic/show?id=a1f9485204d' target=_blank style='color:#2F92EE;'>#帕金森病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=105289, encryptionId=4c671052893a, topicName=帕金森病评定量表), TopicDto(id=96136, encryptionId=bfe3961369b, topicName=量表), TopicDto(id=48520, encryptionId=a1f9485204d, topicName=帕金森病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Feb 18 12:31:12 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2043796, encodeId=7fee2043e96bc, content=<a href='/topic/show?id=0f20139e1cb' target=_blank style='color:#2F92EE;'>#PDR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13971, encryptionId=0f20139e1cb, topicName=PDR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Thu Jun 01 02:40:48 CST 2023, time=2023-06-01, status=1, ipAttribution=)]
    2022-10-27 d830372
  2. [GetPortalCommentsPageByObjectIdResponse(id=1842832, encodeId=dc4c1842832cc, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11422, encryptionId=9f061142249, topicName=MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Thu Oct 27 14:40:48 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115234, encodeId=d03c211523487, content=MDS 统一<a href='/topic/show?id=4c671052893a' target=_blank style='color:#2F92EE;'>#帕金森病评定量表#</a>(MDS-UPDRS)<a href='/topic/show?id=bfe3961369b' target=_blank style='color:#2F92EE;'>#量表#</a><a href='/topic/show?id=a1f9485204d' target=_blank style='color:#2F92EE;'>#帕金森病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=105289, encryptionId=4c671052893a, topicName=帕金森病评定量表), TopicDto(id=96136, encryptionId=bfe3961369b, topicName=量表), TopicDto(id=48520, encryptionId=a1f9485204d, topicName=帕金森病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Feb 18 12:31:12 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2043796, encodeId=7fee2043e96bc, content=<a href='/topic/show?id=0f20139e1cb' target=_blank style='color:#2F92EE;'>#PDR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13971, encryptionId=0f20139e1cb, topicName=PDR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Thu Jun 01 02:40:48 CST 2023, time=2023-06-01, status=1, ipAttribution=)]
    2023-02-18 showtest 来自上海
  3. [GetPortalCommentsPageByObjectIdResponse(id=1842832, encodeId=dc4c1842832cc, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11422, encryptionId=9f061142249, topicName=MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Thu Oct 27 14:40:48 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115234, encodeId=d03c211523487, content=MDS 统一<a href='/topic/show?id=4c671052893a' target=_blank style='color:#2F92EE;'>#帕金森病评定量表#</a>(MDS-UPDRS)<a href='/topic/show?id=bfe3961369b' target=_blank style='color:#2F92EE;'>#量表#</a><a href='/topic/show?id=a1f9485204d' target=_blank style='color:#2F92EE;'>#帕金森病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=105289, encryptionId=4c671052893a, topicName=帕金森病评定量表), TopicDto(id=96136, encryptionId=bfe3961369b, topicName=量表), TopicDto(id=48520, encryptionId=a1f9485204d, topicName=帕金森病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Feb 18 12:31:12 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2043796, encodeId=7fee2043e96bc, content=<a href='/topic/show?id=0f20139e1cb' target=_blank style='color:#2F92EE;'>#PDR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13971, encryptionId=0f20139e1cb, topicName=PDR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Thu Jun 01 02:40:48 CST 2023, time=2023-06-01, status=1, ipAttribution=)]
    2023-06-01 wsusan1966

相关资讯

Neurology:帕金森病患者大脑储备结构测量值与运动进展的关系

近日,一项发表在Neurology上的研究探讨了帕金森病(PD)患者脑储备基线结构测量与临床进展的关系,进一步提供 PD 脑储备结构测量的潜在机制。脑资源较多的 PD 患者有较大的代偿能力。

movement disorders:吸烟和基因相互作用,或促进帕金森发生

尽管这是PD研究中最有力的发现之一,但吸烟和PD之间的逆向关联的机制仍然未知

NEJM:cinpanemab治疗早期帕金森病失败

帕金森病(Parkinsor ' s disease, PD)是目前世界第二大神经退行性疾病。PD是由黑质致密部的多巴胺能神经元大量丢失和α突触核蛋白(α-syn)聚集形成路易

NEJM:Prasinezumab治疗帕金森病再度失败,aSyn靶向免疫疗法前路茫茫

帕金森病(PD)是一种慢性进行性神经变性疾病,其特征是黑质致密部(SNpc)多巴胺能神经元早期变性死亡,细胞内广泛存在aSyn聚集;PD患病率仅次于阿尔茨海默病,是常见的神经变性性疾病,发病率和患病率

FDA批准Buntanetap治疗帕金森病的3期临床试验

阿尔茨海默病(AD)和帕金森病都是老年人中最常见的神经退行性疾病,它困扰全球上千万患者和他们的家人。有没有一种药物同时能治疗这两种疾病的?2021年5月,Annovis Bio公司宣布,该公司的在研疗

Cell:揭开帕金森病标志物的双面角色

Khurana及其同事的最初线索来自α-突触核蛋白毒性的酵母和果蝇模型,并通过对人类细胞,病人来源的神经元和人类遗传学的研究得到证实。